Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

OBJECTIVES:

Primary

• Determine the recommended phase II dose of everolimus when administered with low-dose cisplatin in patients with advanced solid tumors.

Secondary

• Determine the safety and tolerability of this regimen in these patients.
• Describe the pharmacokinetics of this regimen in patients with advanced solid tumors.
• Assess the effects of this regimen on p53 and p21 immunohistochemistry assays of pre- and post-treatment tumor biopsies from patients with recurrent or metastatic solid tumors.

OUTLINE: This is a dose-escalation study of everolimus (part A) followed by a biological marker study (part B).

• Part A (closed to accrual as of 1/2009): Patients receive cisplatin* IV over 30 minutes on days 1, 8, and 15 and oral everolimus* once daily on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of everolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose proceeding that at which 2 of 6 patients experience dose-limiting toxicity (DLT) during course 1. The recommended phase II dose is defined as the dose at which 1 of 6 patients experience DLT during course 1.

Blood is drawn periodically on days 1 and 8 of course 1 for pharmacokinetic studies.

• NOTE: *Patients who have completed 5 courses of treatment and maintain stable disease or better may continue treatment with everolimus alone or in combination with cisplatin
• Part B: Patients undergo biopsy of the primary tumor, metastatic deposit, or involved lymph node. No more than 14 days later, patients receive everolimus at the recommended phase II dose and cisplatin as in part A.

Patients undergo another tumor biopsy on day 15 of course 1, before receiving chemotherapy. The pre- and post-therapy tissue is examined by immunochemistry and analyzed for p53 and p21 expression.

PROJECTED ACCRUAL: A total of 30 people will be accrued for this study.

DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of 1 of the following:

• Advanced solid tumor (part A)

• Confirmation by core biopsy or fine-needle aspiration allowed
• Solid tumor (part B)

• Recurrent or metastatic disease
• Easily accessible for biopsy
• Measurable disease
• No uncontrolled brain or leptomeningeal metastases

• No requirement for glucocorticoids

PATIENT CHARACTERISTICS:

• Karnofsky performance status 70-100%
• Absolute neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin > 10 g/dL
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST and ALT ≤ 2.5 times ULN (< 5 times ULN if liver metastases are present)
• Creatinine normal OR creatinine clearance ≥ 55 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for at least 3 months after completion of study therapy
• No HIV positivity
• No peripheral neuropathy ≥ grade 2
• No hypertriglyceridemia ≥ grade 2
• No impaired gastrointestinal function or gastrointestinal disease that may alter the absorption of everolimus, including any of the following:

• Ulcerative disease
• Uncontrolled nausea
• Vomiting
• Diarrhea
• Malabsorption syndrome
• Small bowel resection
• No other concurrent severe and/or uncontrolled medical disease that would compromise study participation, including any of the following:

• Uncontrolled diabetes
• Unstable angina
• New York Heart Association class III or IV congestive heart failure

PRIOR CONCURRENT THERAPY:

• No more than 3 prior cytotoxic chemotherapy regimens for recurrent or metastatic disease
• At least 4 weeks since prior major surgery and recovered
• At least 4 weeks since prior radiation therapy and recovered
• At least 4 weeks since prior systemic anticancer therapy and recovered
• At least 4 weeks since prior and no other concurrent investigational drugs
• No prior everolimus or other agents specifically targeting mTOR
• No prior radiation therapy to > 25% of the bone marrow
• No prior radiation therapy to the whole pelvis and/or brain
• No concurrent chronic steroid treatment (> 5 mg/day of prednisone)

• Concurrent low-dose steroid replacement regimens (≤ 5 mg/day of prednisone) allowed
• No concurrent immunosuppressive agents
• No other concurrent anticancer agents
• No concurrent agents known to be strong inhibitors or inducers of isoenzyme CYP3A